<DOC>
	<DOC>NCT00195533</DOC>
	<brief_summary>The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for fever in neutropenic patients. Study of consecutive cohorts(2). First the patients will be included in the monotherapy branch until completing the predicted number of cases. When this happens, the Coordinating Center will communicate it to the participant centers and from then the patients will be included in the combined therapy.</brief_summary>
	<brief_title>Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
	<criteria>Patients with hematological malignancy or those who had undergone stem cell transplantation for neoplastic disease. Fever (&gt;38ÂºC) Neutropenia (absolute neutrophil count &lt; 500 or &lt; 1000 anticipated to fall below 500 cells within 2448 hours). Known allergy to any of the antibiotics used in this trial A high probability of death within 48 hours</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myeloma</keyword>
</DOC>